Primary Vitrectomy versus Tap and Inject for Fungal Endophthalmitis: Meta-Analysis and Comparison with Data from a Reference Centre.

PURPOSE: We aimed to compare the visual outcomes after pars plana vitrectomy (PPV) versus tap and inject (T&I) in fungal endophthalmitis (FE) reported in the literature and to compare the findings from the literature with data from a reference centre. METHODS: We performed a systematic review and meta-analysis of studies reporting the use of PPV versus T&I in FE. We also performed a retrospective review of the clinical records of patients with endophthalmitis from a reference centre in Colombia. RESULTS: We included 13 studies with 334 eyes; 53.59% received PPV and 46.4% received T&I. The overall relative risk of improving ≥ 2 lines in PPV versus T&I was 0.98 (95% confidence interval [CI] 0.80-1.22; p = 0.88) with a mean difference of final visual acuity of 0.26 (95% CI 0.12-0.63; p = 0.18). There were no significant differences in subgroup analysis. Data from the reference centre included 32 endophthalmitis cases, 15.6% of which had a fungal aetiology (80% received PPV and 20% T&I). There were no significant differences in the subgroup analysis. CONCLUSIONS: Based on the findings from the literature and the reference centre, T&I is noninferior to PPV. This is the first meta-analysis in the literature evaluating these effects in FE. It is necessary to execute new prospective randomised controlled studies in patients with endophthalmitis.

Central retinal vein occlusion after mRNA SARS-CoV-2 vaccination: A case report.

A central retinal vein occlusion (CRVO) case in a patient developed with sudden blurred vision in some hemifield areas of his left eye, maintaining 20/20 vision 15-days after the COVID-19 vaccination. Initial retinal findings were venous dilation and tortuosity with dispersing dot hemorrhages. Fluorescein angiography (FA) and optical coherence tomography (OCT) confirmed a non-ischemic CRVO diagnosis, and a complete blood panel was requested with average results. An intravitreal steroid dose was applied. A decrease in best-corrected visual acuity (BCVA) (20/30) with more intraretinal hemorrhages was documented. An intravitreal dose of bevacizumab and oral apixaban were added with a final BCVA of 20/20 with decreased hemorrhages. There is no specific causal relationship between COVID-19 vaccines and CRVO. Without previous risk factors and positive treatment response, this case may correlate the first COVID-19 vaccine dose and the event.

Interventions for Demodex blepharitis and their effectiveness: A systematic review and meta-analysis.

PURPOSE: A systematic review and meta-analysis was performed to evaluate the effectiveness of interventions in the treatment ofDemodex blepharitis in adult patients. METHODS: A systematic review and meta-analysis of studies reporting the efficacy of treatments forDemodex blepharitis in the main databases (PubMed / Scopus / Cochrane / EMBASE / Science Direct / WOS / Scielo / Google Scholar / metaRegister of Controlled Trials / ClinicalTrials.gov/ WHO ICTRP) until November 24, 2020 was performed according to the PRISMA statement for meta-analysis. RESULTS: Overall, 18 studies were included for 29 different interventions in 1195 participants with 1574 eyes that were positive for Demodex Spp. Demodex counts, total eradication, clinical improvement, Ocular Surface Disease Index, Tear Break-Up Time, cylindrical dandruff, Schirmer test, osmolarity and adverse reactions were analysed, and stratified sub-analyses conducted. The overall effects for Demodex count (mean difference), total eradication (risk ratio) and adverse reactions (risk difference) were -2.07 (95 % CI -3.99 to -0.15) p = 0.03, 1.84 (95 % CI 1.27-2.66) p = 0.001 and 0.24 (95 % CI 0.08 to 0.41) p = 0.005, respectively. The most frequent interventions evaluated in the included studies were tea tree oil (TTO) and its derivatives, such as terpinen 4-ol. CONCLUSION: Multiple therapeutic choices were evaluated in this meta-analysis. Pharmacological interventions were superior to non-pharmacological (mechanical, thermal and pulsed light) interventions. It was not possible to establish significant differences between TTO and non-TTO-derived treatments. Adverse reactions were more frequent in TTO-derived treatments, however all were mild. It is necessary to execute studies with longer follow-up times to determine whether re-infestation occurs after the administration of different treatments.

Topical ivermectin-metronidazole gel therapy in the treatment of blepharitis caused by Demodex spp.: A randomized clinical trial.

PURPOSE: To evaluate the efficacy of topical ivermectin-metronidazole combined therapy in the management of Demodex-associatedblepharitis. METHODS: Sixty patients with a diagnosis of Demodex-associatedblepharitis were recruited in a randomized clinical trial. Thirty receiving topical ivermectin (0.1%)-metronidazole (1%) gel treatment on days 0, 15 and 30. Thirty additional patients were used as a control group receiving vehicle on days 0, 15 and 30. The primary efficacy measure was the number of Demodex spp. mitesin the eyelashes of patients. The secondary outcomes included clinical improvement of signs and adverse events. RESULTS: Complete eradication of Demodex spp. was found in 96.6% of patients in the treatment group. Furthermore, a significant reduction of inflammation signs were found in all treated patients versus controls. None of the patients experienced any adverse effects associated with the treatment. CONCLUSION: Demodex infection was controlled satisfactorily with the ivermectin (0.1%)-metronidazole (1%) gel, and no adverse effects were observed. Application of this gel for the treatment of different parasitic infections of the eyelids could be feasible, and this requires further exploration.

Oclusión vascular mixta de la retina en una paciente con síndrome antifosfolípido. Reporte de caso / Mixed retinal vascular occlusion secondary to antiphospholipid antibody syndrome. A case report

Introducción: La oclusión combinada de la arteria y la vena central de la retina es un evento vascular poco frecuente, caracterizado por pérdida visual súbita y pronóstico reservado. Los pocos casos reportados se asocian con antecedentes de patología sistémica vasculítica, reumatológica, infecciosa o tumoral. Objetivo: Describir un caso de doble oclusión vascular retiniana secundario a síndrome de anticuerpos antifosfolípidos. Resumen del caso: Se reporta el caso de una paciente de 31 años con oclusión de vena y arteria central de la retina, con historia clínica y paraclínicos compatibles con un síndrome de anticuerpos antifosfolípidos de base, enfermedad de difícil manejo con un pobre pronóstico visual, con secuelas visuales graves, rápidas e irreversibles. Conclusiones: Las oclusiones vasculares combinadas de arteria y vena central de la retina son poco frecuentes. Se caracterizan por pérdida súbita de la visión y hallazgos clínicos propios de ambos tipos de oclusiones: palidez retinal, mancha de color rojo cereza, dilatación venosa, hemorragias en llama, edema de disco, etc. Por lo regular tiende a relacionarse con patologías infecciosas, autoinmunitarias o tumorales, entre otras, como es el caso del síndrome antifosfolípido. Las opciones terapéuticas son limitadas y la respuesta es incierta, con un mal pronóstico visual y secuelas irreversibles

Introduction: Combined vascular occlusion of the central retinal artery and vein is a rare vascular event, characterized by sudden visual loss and uncertain prognosis. The few cases reported in literature are associated with a history of vasculitic, rheumatological, infectious or tumoral pathology. Objective: To describe a mixed retinal vascular occlusion secondary to antiphospholipid antibody syndrome. Case summary: We report a case with mixed retinal vascular occlusion in a patient with history of antiphospholipid antibody syndrome , with poor visual prognosis, difficult treatment and severe irreversible sequelae. Conclusions: Combined retinal vascular occlusions are rare entities characterized by sudden vision loss and clinical findings of both types of occlusions: retinal pallor, cherry red spot, venous dilatation, hemorrhages, disc edema, etc. Usually, these are related to infectious, autoimmune or neoplasic diseases, like antiphospholipid syndrome. The therapeutic options are limited and their effectiveness is vague, leading to poor visual prognosis and irreversible sequelae

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic.

A novel coronavirus (SARS-CoV-2), causing an emerging coronavirus disease (COVID-19), first detected in Wuhan City, Hubei Province, China, which has taken a catastrophic turn with high toll rates in China and subsequently spreading across the globe. The rapid spread of this virus to more than 210 countries while affecting more than 25 million people and causing more than 843,000 human deaths, it has resulted in a pandemic situation in the world. The SARS-CoV-2 virus belongs to the genus Betacoronavirus, like MERS-CoV and SARS-CoV, all of which originated in bats. It is highly contagious, causing symptoms like fever, dyspnea, asthenia and pneumonia, thrombocytopenia, and the severely infected patients succumb to the disease. Coronaviruses (CoVs) among all known RNA viruses have the largest genomes ranging from 26 to 32 kb in length. Extensive research has been conducted to understand the molecular basis of the SARS-CoV-2 infection and evolution, develop effective therapeutics, antiviral drugs, and vaccines, and to design rapid and confirmatory viral diagnostics as well as adopt appropriate prevention and control strategies. To date, August 30, 2020, no effective, proven therapeutic antibodies or specific drugs, and vaccines have turned up. In this review article, we describe the underlying molecular organization and phylogenetic analysis of the coronaviruses, including the SARS-CoV-2, and recent advances in diagnosis and vaccine development in brief and focusing mainly on developing potential therapeutic options that can be explored to manage this pandemic virus infection, which would help in valid countering of COVID-19.

SARS-CoV-2 jumping the species barrier: Zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus.

Coronavirus Disease 2019 (COVID-19), caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome - Coronavirus-2) of the family Coronaviridae, appeared in China in December 2019. This disease was declared as posing Public Health International Emergency by World Health Organization on January 30, 2020, attained the status of a very high-risk category on February 29, and now having a pandemic status (March 11). COVID-19 has presently spread to more than 215 countries/territories while killing nearly 0.75 million humans out of cumulative confirmed infected asymptomatic or symptomatic cases accounting to almost 20.5 million as of August 12, 2020, within a short period of just a few months. Researchers worldwide are pacing with high efforts to counter the spread of this virus and to design effective vaccines and therapeutics/drugs. Few of the studies have shown the potential of the animal-human interface and zoonotic links in the origin of SARS-CoV-2. Exploring the possible zoonosis and revealing the factors responsible for its initial transmission from animals to humans will pave ways to design and implement effective preventive and control strategies to counter the COVID-19. The present review presents a comprehensive overview of COVID-19 and SARS-CoV-2, with emphasis on the role of animals and their jumping the cross-species barriers, experiences learned from SARS- and MERS-CoVs, zoonotic links, and spillover events, transmission to humans and rapid spread, and highlights the new advances in diagnosis, vaccine and therapies, preventive and control measures, one health concept along with recent research developments to counter this pandemic disease.

Fatal Zika virus infection in the Americas: A systematic review.

INTRODUCTION: While death due to Zika virus (ZIKV) infection has been described, reports of fatal cases have been infrequent and no systematic reviews on the subject have been published. METHODS: A systematic review of the literature in four databases was performed to assess fatal outcomes of postnatal ZIKV infection and the available evidence that links ZIKV infection to death. RESULTS: Three hundred and eleven articles were retrieved; 20 of them were epidemiological reports from surveillance agencies and ministries of health. After screening by abstract and title, 59 articles were selected for full-text assessment. Of these, 35 were excluded (with reasons) and 24 were finally included for qualitative analysis. A total of 51 reported deaths associated with ZIKV infection in nine countries were identified. The majority of cases (56.9%) were not related to Guillain-Barré syndrome. Cases from three countries accounted for 67.6% of the deaths. ZIKV infection was laboratory-confirmed in the majority of cases (64.7%). DISCUSSION: ZIKV was not considered to be a dangerous, and much less a lethal pathogen, until very recently. However, an increasing number of fatalities have been published in the literature since the first death was reported in 2016. Additional research is needed to elucidate factors that may mediate the pathogenesis of severe, atypical, and fatal disease.

Bibliometric Assessment of the Global Scientific Production of Nitazoxanide.

INTRODUCTION: Nitazoxanide is a member of a new class of drug, thiazolides, and it was discovered in 1984 with antimicrobial activity effect against anaerobic bacteria, Hepatitis virus, protozoa, and helminths. METHODS: A bibliometric study on four databases (1984-2016) - Medline, Scopus, LILACS, and SciELO - characterizing the global scientific production of nitazoxanide. We determined the quantity, quality (number of citations), and types of studies developed by each country, characterizing them by years, international cooperation, development, place of publication, authors (with its H-index), and groups with higher impact. RESULTS: There were 512 articles in Medline - the higher scientific production is from the USA (19.71%), Switzerland (7.51%), and Mexico (7.27%). There were 1,440 articles in Scopus - from the USA (8.98%), Mexico (2.13%), and India (1.65%). There were 405 articles in LILACS - from Mexico (4.69%), the USA (4.2%), and Peru (2.47%). There were 47 articles in SciELO - from Brazil (34.04%), Venezuela (21.28%), and Colombia (14.89%). The H-index of nitazoxanide is 75 - the USA (26), Egypt (12), and Canada (10) were the countries contributing more with that. CONCLUSIONS: Nitazoxanide research has been highly important. Nevertheless, it is relatively limited when compared with other drugs. Its research has been led by the USA, as revealed in this bibliometric assessment. Although some developing countries, where it is used especially for protozoa and helminths, probably have its influence, and this explains the fact that Mexico and India, among others, are the top countries in the scientific production of this anti-infective agent. This bibliometric study evidenced a relatively low number of publications, however, it has been increased in recent years.

Ophthalmologic aspects of chikungunya infection.

Chikungunya fever, a viral disease epidemic in some parts of the world is newly introduced in the Americas. This is of considerable international concern, with a growing incidence owing to developing urbanization, tourism, and trade. Ocular manifestations of chikungunya fever are not frequent, but of great relevance. Common manifestations include conjunctivitis, optic neuritis, iridocyclitis, episcleritis, retinitis and uveitis. Diagnostic and monitoring investigations would include optical coherence tomography, fundus fluorescein and indocyanine green angiography, visual field analysis, and electrophysiologic tests. There have been no prospective, randomized therapeutic trials, and it is unclear if the disease is self-limiting or if treatment is actually beneficial. Prognosis varies, ranging from full resolution to permanent vision loss despite intervention.

Prevalencia de potenciales interacciones farmacológicas de Azitromicina en Colombia, 2012-2013 / Prevalence of potential drug interactions with azithromycin in Colombia, 2012-2013

Objetivos Determinar la prevalencia de potenciales interacciones farmacológicas entre azitromicina y diferentes antiarrítmicos del grupo IA y III en una base de datos de prescripción de medicamentos a nivel nacional durante el año 2012-2013. Métodos Estudio retrospectivo a partir de una base de datos poblacional de dispensación de medicamentos. Se extrajeron datos de los pacientes que recibieron azitromicina desde 1 de enero de 2012 a 30 junio de 2013, al igual que pacientes que recibieron este antibiótico en combinación a otros medicamentos con demostrado riesgo de provocar arritmias cardíacas al usarse concomitantemente. Se establecieron frecuencias y proporciones. Resultados Se identificaron 13 859 pacientes que recibieron azitromicina sola o en combinación con otros medicamentos. El tiempo promedio de uso fue 4,5±0,9 días; Un total de 702 pacientes (5,1 %) recibieron azitromicina más otros 19 fármacos de potencial riesgo. Los más frecuentemente asociados fueron: loratadina (77,1 %), difenhidramina (16,5 %) y amitriptilina (8,1 %). Las combinaciones con un solo medicamento fueron las más frecuentes (n=533, 75,9 %), con predominio de azitromicina+loratadina. El máximo número de fármacos combinados fue seis (n=2, 0,3 %). Conclusiones La identificación mediante bases de datos poblacionales la prescripción de medicamentos, es una manera eficaz de encontrar potenciales interacciones entre estos. La frecuencia de potenciales interacciones entre azitromicina y otros fármacos es común en pacientes colombianos. Se debe estimar el riesgo de ocurrencia de eventos cardiacos adversos.(AU)

Objective To determine the prevalence of potential drug interactions between azithromycin and different IA and III antiarrhythmic groups in a national database of drug prescriptions in 2012-2013. Methods Retrospective study based on a population database of medicine dispensation. Data from patients who received azithromycin between January 1, 2012 and June 30, 2013 were extracted along with data from patients who received azithromycin in combination with other medications shown to cause heart arrhythmias when used concomitantly. Frequencies and proportions were established. Results 13 859 patients receiving azithromycin alone or in combination with other drugs were identified. The average time of use was 4.5 ± 0.9 days. A total of 702 patients (5.1 %) received azithromycin plus 19 other potentially risky drugs. The most frequently associated were loratadine (77.1 %), diphenhydramine (16.5 %) and amitriptyline (8.1 %). Combinations with a single drug were the most frequent (n=533, 75.9 %), predominantly azithromycin+loratadine. The maximum number of combined drugs was six (n=2, 0.3 %). Conclusions Identification of drug prescriptions through population databases is an effective way to find potential drug interactions. The frequency of potential interactions between azithromycin and other drugs is common in Colombian patients. Future research should assess the risk of occurrence of adverse cardiac events.(AU)

Ocular toxocariasis: new diagnostic and therapeutic perspectives.

PURPOSE: To provide an updated insight of concepts regarding the overview, epidemiology, risk factors, clinical manifestations, diagnosis, treatment and prevention of ocular toxocariasis. DESIGN: Perspective of literature review. METHODS: Review and synthesis of literature about toxocariasis, with interpretation and perspective. A literature search for "ocular toxocariasis" was performed using PubMed, ScienceDirect, Scopus, SciELO and LILACS databases. RESULTS: Mild to moderate infections are frequently reported in ocular toxocariasis which usually occurs in children and typically presents as unilateral vision impairment, blindness is common and could present invasion of the retina. There are three groups of presentation of toxocariasis (according to the physical examination): chronic endophthalmitis, posterior granuloma and peripheral granuloma. Standard diagnosis of ocular toxocariasis is based on the identification of clinical signs, supported by additional diagnostic methods. Regarding treatment, there is no commonly accepted regimen but most of the authors prefer to use steroids and anthelminthic agents, but nowadays there are no standardized parameters in terms of dosage, duration and route of administration. Surgery has been recommended in some cases. CONCLUSION: Toxocariasis is still a problem of public health, particularly in developing countries with an increasing epidemiological burden in terms of morbidity and mortality and most of the authors agree on the utmost relevance of its prevention. Clinical experience and suspicion of ophthalmologists make an important role in its diagnosis, but always with supportive diagnostic methods. Additional studies should explore new therapeutic options for toxocariasis.

[Prevalence of potential drug interactions with azithromycin in Colombia, 2012-2013]. / Prevalencia de potenciales interacciones farmacológicas de Azitromicina en Colombia, 2012-2013.

Objective To determine the prevalence of potential drug interactions between azithromycin and different IA and III antiarrhythmic groups in a national database of drug prescriptions in 2012-2013. Methods Retrospective study based on a population database of medicine dispensation. Data from patients who received azithromycin between January 1, 2012 and June 30, 2013 were extracted along with data from patients who received azithromycin in combination with other medications shown to cause heart arrhythmias when used concomitantly. Frequencies and proportions were established. Results 13 859 patients receiving azithromycin alone or in combination with other drugs were identified. The average time of use was 4.5 ± 0.9 days. A total of 702 patients (5.1 %) received azithromycin plus 19 other potentially risky drugs. The most frequently associated were loratadine (77.1 %), diphenhydramine (16.5 %) and amitriptyline (8.1 %). Combinations with a single drug were the most frequent (n=533, 75.9 %), predominantly azithromycin+loratadine. The maximum number of combined drugs was six (n=2, 0.3 %). Conclusions Identification of drug prescriptions through population databases is an effective way to find potential drug interactions. The frequency of potential interactions between azithromycin and other drugs is common in Colombian patients. Future research should assess the risk of occurrence of adverse cardiac events.

Bibliometric assessment of the Latin-American contributions in dengue.

BACKGROUND: Despite efforts in prevention and control of dengue, it is still a public health problem in the region. There are estimations of 13 million people affected in the Americas, therefore, it is of outmost importance to research it. An assessment on the Latin- American contributions on dengue was done. METHODS: Bibliometric study at SCI (1980- 2013), MEDLINE/GOPUBMED (1802-2013), Scopus (1959-2013), SCIELO (2004-2013), LILACS (1980- 2013). Different study types, characterized by years, city/country of origin, journals and more productive authors, by country, cites and H index have been conducted. RESULTS: At SCI, 2598 articles were retrieved (21% of the total). Brazil was found to be the highest contributor (31.2%), then Puerto Rico (12.9%) and Mexico (10.7%). At Scopus, there are 2646 articles (16.7% of the total), 31.2% Brazil, 11.1% Mexico, 9.3% Cuba; the region received 41881 citations, 25.4% from Brazil (H index=45), 14.4% Cuba (H index=35) and 12.88% Puerto Rico (H index=38); 9.1% in Brazil were from Fundação Oswaldo Cruz; 1.6% of Mexico corresponded to Instituto Nacional de Salud Publica, 4.9% of Cuba are from Instituto de Medicina Tropical Pedro Kouri. At Medline, there are 2799 records (33.9% from Brazil). At SciELO there are 825 records (46.6% Brazil). At LILACS, there are 1178 records (46.8% Brazil). CONCLUSIONS: Brazil is the best producer in the region. In Puerto Rico and Brazil, there observed the epidemiologic burden of the disease. Scientific production in bibliographical data bases, particularly regional, is low, as compared to the high impact of the disease of in urban zones of the region.

Bibliometric assessment of the contributions of literature on Chagas disease in Latin America and the Caribbean.

Chagas disease, considered a parasitic neglected disease, is endemic in Latin America. Although, its mortality rate has decreased over time, it still represents a public health problem in the region. A bibliometric evaluation of the Latin American contributions on this disease was done. This study used SCI (1980-2013), MEDLINE/GOPUBMED (1802-2013), Scopus (1959-2013), SCIELO (2004-2013), and LILACS (1980-2013). Different study types have been characterized by years, origin city/country, journals and most productive authors, by country, cites and H-index. 2988 articles were retrieved from SCI (30.85% of total). Brazil was found to be the highest producer (31.22%), followed by Argentina (18.14%) and México (9.57%); the region received 47241 citations, 28.60% for Brazil (H-index=52), 18.26% of Argentina (Hindex= 43), 11.40% Bolivia (H-index=37). 4484 were retrieved from Scopus (30.20% of the total), 38.58% of which were from Brazil, 12.40% from Argentina and 8.90% from Mexico. From Medline, 6647 records were retrieved (45.58% Brazil). From SciELO, 917 articles (47.66% Brazil). From LILACS, 2165 articles (60.05% Brazil). Brazil has the highest output in the region. Despite advances in controlling Chagas disease, scientific production is low, particularly for regional bibliographic databases, which calls for more research on this disease.